RAAS blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis

Upinder Kaur[1], Sankha Shubhra Chakrabarti[2], Tejas Kumar Patel[3#]

1: MD, Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India

2: MD, Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India

3: MD, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, UP, India

#Corresponding author: Dr Tejas Kumar Patel, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, UP, India

Email: dr.tkp2006@yahoo.co.in Phone: +919909105876

Abstract:

Background: Coronavirus disease 2019 (COVID-19) has evolved as a global crisis with high mortality seen in elderly and people with cardiometabolic diseases. The use of renin angiotensin aldosterone system (RAAS) blockers in these patients is known to enhance the expression of ACE-2, the chief binding receptor of SARS-CoV-2 and may potentially enhance infectivity.

Objective: To provide a pooled estimate of the effect of RAAS blocker usage on COVID-19 outcomes.

Data Sources: An electronic literature search was performed for published (using MEDLINE/PubMed and Google Scholar) and preprint (using bioRxiv and medRxiv) studies of interest. The last search was conducted on 9th July 2020.

Study Selection: Studies reporting data on RAAS blocker use and COVID-19 mortality and severity were included in the review.

Data Extraction and Synthesis: Mortality data and severity data including hospitalization, intensive care unit (ICU) admission, invasive ventilation, steroid use and acute kidney injury (AKI) were recorded. Pooled Odds ratio (OR) estimates were reported with 95% CIs and level of heterogeneity (I^2).

Main Outcomes and Measures: Odds of mortality in users of RAAS blockers with respect to non-users was the primary outcome. Odds of severity, hospitalization, ICU admission, mechanical ventilation, steroid use, and AKI in users with respect to non-users of RAAS blockers were the secondary outcomes.

Results: Of 1348 articles identified, 48 published studies were included in the final analysis, with a total of 26432 patients from 31 studies included in mortality analysis and 20127 patients from 23 studies included in severity analysis. Majority of the studies (41.6%) were from China. No increased risk of mortality (Pooled OR 0.91 (0.65-1.26), I^2=89%) or severity (Pooled OR 1.08 (0.79-1.46), I^2=88%) was seen with RAAS blockers. The drug class was protective in hypertension (pooled OR 0.63 (0.46-0.86), I^2=58%). Severity of COVID-19 outcomes was found to be high for Europeans (Pooled OR 2.08 (1.52-2.85), I^2=77%) and US patients (Pooled OR 1.87 (1.62-2.17) in users of RAAS-blockers. A nearly 4 times higher risk of hospitalization, two times higher risk of ICU admission and mechanical ventilation was observed in US patients on RAAS blockers. No net effect on mortality and severity outcomes

was seen in Chinese patients. RAAS blocker usage did not have any effect on corticosteroid use and AKI in Chinese patients.

Conclusions and Relevance: Use of RAAS blockers is not associated with increased risk of mortality in COVID-19 patients. Reduced mortality is seen in hypertensive patients with COVID-19 and therefore the drugs should be continued in this subset. US and European patients are at higher risk of severe outcomes. Pharmacogenomic differences may explain the ethnicity related variations.

Keywords: RAAS, Regional, Hypertension, Mortality, Severity, Genetic polymorphisms

1. Introduction

Corona Virus Disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) has affected 24,652,652 individuals worldwide and claimed 836,065 lives as of 28th August 2020.(1) ACE2 is the major binding receptor of SARS-CoV-2 and is located on pulmonary epithelial cells, endothelial cells and in cells of the kidney, among others. Acute respiratory distress syndrome, myocardial injury, multiorgan failure and disseminated intravascular coagulation (DIC) including diffuse pulmonary intravascular coagulopathy are responsible for majority of the deaths and stem from a state of inflammatory cytokine storm and vascular thrombosis.(2,3) Older individuals and those with co-morbidities such as hypertension, diabetes mellitus (DM) and ischaemic heart disease (IHD) are at increased risk of a severe form of the disease. The use of renin-angiotensin-aldosterone system (RAAS) blockers such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and mineralocorticoid receptor antagonists (MRAs) in such patients is not uncommon. With experimental evidence of upregulation of ACE2 by RAAS blockers, some concerns were raised related to the increased risk of infection and severity of disease in the users of these drugs.(4,5)

Following this, multiple observational studies were conducted to assess the relationship between the use of RAAS blockers and severity of COVID-19. This systematic review and meta-analysis aim to compile the information obtained from these clinical studies and elucidate the association between the use of RAAS blockers and clinical outcomes in patients of COVID-19. In the past few months, few such meta-analyses have been published but were limited due to the inclusion of small numbers of studies. The current meta-analysis of 48 studies provides the most comprehensive view of the issue till date by involving

a much larger number of patients and analysing for multiple health outcomes, as well as by performing region-specific analyses.

2. Methods:

2.1. Search Criteria: A comprehensive search was conducted in PubMed, Google Scholar and the preprint servers medrRxiv.org and bioRxiv.org using keywords: ACEI OR ACE-I OR Angiotensin converting enzyme inhibitors AND COVID-19/SARS-CoV-2, Angiotensin receptor blocker OR AT-1 receptor blocker OR Ang II blocker OR ARB AND COVID-19/SARS-CoV-2, RAAS blocker AND COVID-19/SARS-CoV-2, Aldosterone antagonist AND COVID-19/SARS-CoV-2, Renin inhibitor AND COVID-19/SARS-CoV-2. The final search was conducted on 9th July 2020. Only articles published in English language were included in this study.

2.2. Selection Criteria:

2.2.1. Inclusion criteria

- All clinical studies (observational studies and clinical trials) analysing the effect of RAAS blockers on clinical outcomes in patients of laboratory confirmed COVID-19 were included in this study. Thus, the review involved inclusion of studies which compared the disease outcomes between users and non-users of RAAS blockers as well as those which assessed the use of RAAS blockers in COVID-19 patients of varying severity. The term RAAS blockers include ACEIs, ARBs, aldosterone antagonists and renin inhibitors. Studies were considered irrespective of the dose and duration of RAAS blocker use.

- Studies should have provided comparative data of mortality and/or severity between users and non-users of RAAS blockers in patients of COVID-19.

- All types of study setting (outpatient, inpatient, nursing homes, home care approach) were included.

- All age groups of study population were included

2.2.2. Exclusion criteria

- Studies focusing on individual RAAS blockers only.

- Studies focusing only on outcomes based on laboratory parameters (e.g., serum or urinary ACE2 expression).

- Non-comparative studies, review articles, in-vitro studies, animal studies, viewpoints.

All relevant abstracts were scrutinized, and full text was searched for those found useful. In case of lack of clarity in the abstracts, full text was analysed. This was done by author UK assisted by author SSC and confirmed by author TKP assisted by author SSC.

2.3. Data Extraction:

From the included studies, data was extracted in a Microsoft Excel Sheet. Data included author name, publication year, country, study design, total duration of study, mean or median follow up, characteristics of patients or specific population of COVID-19 patients in whom the particular study was conducted, age, gender, sample size, use of RAAS blockers, mortality outcomes, severity outcomes, need of hospitalization, care in intensive care unit (ICU), need of mechanical ventilation, corticosteroid use and occurrence of acute kidney injury (AKI).

2.4. Risk of bias: Two investigators (TKP and SSC) assessed the risk of bias in the included studies as per the Newcastle - Ottawa quality assessment scale (NOS) adapted for the cross-sectional design. The criteria considered were representativeness of the study sample, sample size, non-respondents, ascertainment of the exposure, comparability of study groups for the confounders (age and major co-morbidities), assessment of outcome and statistical tests. The maximum possible score was 10.(6)

2.5. Outcomes

The primary outcome was odds of mortality in the users of RAAS blockers with respect to non-users among confirmed cases of COVID-19. The secondary outcomes were odds of severity, hospitalization, ICU admission, mechanical ventilation, steroid use, and AKI in users of RAAS blockers with respect to non-users. In the absence of universally accepted definitions, severity was considered as defined by the authors in the included studies. When outcomes were reported both under 'critical' and 'severe' headings, we considered the more serious outcome under severity analysis. In case of multiple time-point for the outcome estimation, we considered data at the end of study period.

A subgroup analysis of all outcomes was performed based on the geographical locations (country or continent of origin) of the included studies. The mortality outcome was further analysed as per study sub-populations (e.g., patients with hypertension). The severity outcome was stratified based on definitions considered by individual authors. A sensitivity analysis was performed for each outcome after excluding studies with high risk of bias. The studies with score $\leq$ 7 on the modified NOS scale were considered to have high risk of bias.

2.6. Data synthesis

All outcomes were dichotomous variables. They are reported as odds ratio (OR) with 95% confidence intervals (CI). The meta-analysis was weighted with inverse variance method. An I^2 test was used to assess the heterogeneity between the studies. Fixed-effect model was used if heterogeneity was less than 50% and random-effect was applied in case heterogeneity exceeded 50%. Funnel plot method was used for reporting publication bias. The meta-analysis was performed using Review Manager Software version 5.4.

3. Results

3.1. Characteristics of included studies

As shown in **Figure 1**, a total of 1348 articles were retrieved. Out of 70 full text articles assessed, 48 studies satisfying the selection criteria were included for detailed qualitative and quantitative analysis in this review. **Table 1** shows the demographic features of the patients in included studies.(3,7–52) Majority of the studies assessing the outcomes of interest have been reported from China (N=20, 41.6%) followed by Europe (N=16, 33.3%). The sample size of individual studies varied from 36 to 9519. In case of 31 (64.5%) studies, mean or median age of patients was more than 60 years.

A total of 32 (66.7%) studies assessed mortality out of which 31 were included in mortality analysis as raw data was not available in the study by Zhang P et al.(45) A total of 35 studies (77.8%) assessed composite severity or individual health outcomes (hospitalization, ICU admission, mechanical ventilation, steroid use, and AKI). Twelve studies defined severity as per clinical guidelines of the National Health Commission of China. Six studies defined severity as the composite of ICU admission and death. Two studies used the severity definition issued by the Infectious Diseases Society of America (IDSA). Composite of hospitalization for ≥ 7 days and death, composite of death/ severe infection

(definition described in the table legend), and composite of SARS/ ICU admission were taken as severe outcome in one study each. In seventeen studies, severity was considered based on individual health outcomes such as ICU admission, invasive ventilation, AKI, and hospitalization as mentioned in **Table 1**. RAAS blockers were used for hypertension in 21 studies (43.7%) while indication of their use was not mentioned in 25 studies (52%). Duration of follow up was mentioned in 14 studies and ranged from 7-32 days. Confounder adjustment had been performed in 22 (45.8%) studies for two major confounders. A total of 30 studies were considered to have low risk of bias.

3.2. Mortality analysis

A total of 26432 patients from 31 studies (6030 users of RAAS blockers and 20402 non- users) were included in the mortality analysis. The use of RAAS blockers was not associated with increased risk of mortality (pooled OR 0.91 (0.65-1.26), I^2= 89%) (**Figure 2**). A similar trend was observed in the sensitivity analysis after excluding studies with high risk of bias (pooled OR 1.09 (0.71-1.67, I^2= 91%). Funnel plot was asymmetrical on visual inspection (**Supplementary Figure 1**).

The subgroup analysis of mortality outcome based on geographical locations showed use of RAAS blockers conferred a protection from mortality in the Chinese population (OR 0.71 (0.52-0.97)) (**Figure 2**). However, in sensitivity analysis, no difference in mortality was observed in studies with low risk of bias (pooled OR 0.85 (0.48-1.50), I^2 =25%). Neither benefit nor risk was observed with the use of RAAS blockers in patients in the US (pooled OR 0.96 (0.59-1.56), I^2 = 81%), Europe (pooled OR 1.19 (0.74-1.91), I^2 =89%), and South Korea (pooled OR 1.12 (0.18-7.01), I^2 =97%) (**Figure 2**). The results were consistent in sensitivity analysis (**Table 2**).

On indication or disease-wise comparison, use of RAAS blockers was found to reduce the overall risk of mortality when prescribed for hypertension (pooled OR 0.63 (0.46-0.86), I^2=58%). Similar trend was observed in sensitivity analysis (pooled OR 0.48 (0.36-0.63), I^2=0%). Ten out of fifteen studies reporting mortality in hypertensive patients were from China. (**Figure 3**). The results were consistent in sensitivity analysis (pooled OR 1.81 (1.28-2.58), I^2 =81%).

3.3. Severity analysis

A total of 20127 patients (5460 RAAS blocker users & 14667 non-users) from 23 studies were included in the severity analysis. The overall pooled summary showed no effect on the severity of disease with the use of RAAS blockers (pooled OR 1.08 (0.79-1.46), I^2=88%) (**Figure 4**). A similar result was observed in sensitivity analysis (pooled OR 1.32 (0.93-1.87), I^2=91%). Funnel plot was asymmetrical on visual inspection (**Supplementary Figure 2**).

Comparison of studies with respect to the definition of severity showed a protective effect of RAAS blockers against 'critical' disease defined by National Health Commission of China (pooled OR 0.5 (0.33-0.76), I^2=29%). Seven out of eight studies assessing this parameter were from China. The effect, however, was nullified on sensitivity analysis (pooled OR 0.63 (0.28-1.45), I^2=70%). On the other hand, RAAS blockers were found to increase the risk of composite outcome of ICU and death (pooled OR 1.82 (1.31-2.53), I^2=82%) with a similar trend in sensitivity analysis. Among the four studies showing negative impact of RAAS blockers, three involved the European population, one enrolled US patients while none was from China (**Figure 4**).(24,34,40,51)

Region/country specific analysis also showed an increased risk of poor health outcomes in European patients (pooled OR 2.08 (1.52-2.85), I^2=77%) and US

patients (OR 1.87 (1.62-2.17)) (**Figure 5**). A similar trend was observed in sensitivity analysis. In contrast, no effect on severity with the use of RAAS blockers was evident in the Chinese population in overall (pooled OR 0.69 (0.45-1.06), I^2=51%), and sensitivity analysis (pooled OR 0.68 (0.3-1.53), I^2=58%) (**Figure 5**).

3.4. Hospitalization

Risk of hospitalization was analysed in seven studies with 13849 patients (2565 RAAS blocker users and 11284 non-users). The use of RAAS blockers was associated with increased risk of hospitalization in overall analysis (pooled OR 2.1 (1.09-4.05), I^2=96%) as well as in sensitivity analysis (pooled OR 2.36 (1.2-4.65), I^2=95%). Among the seven studies, four involved US patients, three enrolled Europeans while none was from China.(8,9,14,18,25,32,33) Country specific subgroup and sensitivity analysis showed a nearly 4 times higher risk of hospitalisation in US patients (pooled OR 3.87 (1.21-12.34), I^2=97%) while no such risk was evident in Europeans (pooled OR 1.17 (0.20-6.82), I^2=95%) (**Supplementary Figure 3**).

3.5. ICU admission

A total of 16441 patients (4060 RAAS blocker users and 12381 non-users) from 13 studies were analysed for the assessment of risk of ICU admission. No increased risk of ICU admission was observed with the use of RAAS blockers in the overall (pooled OR 1.37 (0.86-2.19), I^2=91%) and sensitivity analyses (pooled OR 1.55 (0.79-3.02), I^2=93%). Country-specific analysis showed an increased risk of ICU admission in the US population in overall (pooled OR 1.47 (1.15-1.87), I^2= 37%) and sensitivity analyses (pooled OR 1.82 (1.29-2.58), I^2=0%). No effect on ICU admission was observed in Chinese patients

(pooled OR 0.65 (0.25-1.68), I^2=0%) or in Europeans (pooled OR 1.51 (0.57-4.03), I^2=93%) (**Supplementary Figure 4**).

3.6. Invasive ventilation

Need for invasive ventilation was assessed in 15 studies with a total of 10318 patients. Use of RAAS blockers was not associated with increased requirement of invasive ventilation (pooled OR 1.06 (0.7-1.59), I^2=80%) and the result did not vary in sensitivity analysis (pooled OR 1.28 (0.58-2.83), I^2=88%). Country-specific analysis showed an increased risk of invasive ventilation in the US population (pooled OR 2.33 (1.02- 5.36), I^2=92%). After excluding the studies with a high risk of bias, sensitivity analysis could be performed on one study by Mehta et al which showed a significantly high risk of invasive ventilation with RAAS blocker usage (OR 9.72 (4.35-21.71)).(25) No such risk was seen in the Chinese population (pooled OR 0.79 (0.55-1.14), I^2=0%) or in Europeans (pooled OR 0.64 (0.17-2.46), I^2=86%). Similar trends were observed in the Chinese and Europeans in sensitivity analysis (pooled OR for Chinese population 1.03 (0.45-2.37), I^2= 50%; pooled OR for Europeans 0.64 (0.17-2.46), I^2=86%) (**Supplementary Figure 5**).

3.7. Corticosteroid use

Seven studies (n=1854) commented on corticosteroid use in relation to RAAS blocker use. All of these were from China. Use of RAAS blockers did not affect the requirement for corticosteroid use in the overall analysis (pooled OR 0.82 (0.65-1.04), I^2=38%) and also in the sensitivity analysis (pooled OR 1.01 (0.64-1.6), I^2= 35%) (**Supplementary Figure 6**).

3.8. Acute kidney injury

Five studies (n=2143) reporting on AKI were analysed. Use of RAAS blockers was not associated with increased or decreased risk of AKI in overall analysis (pooled OR 0.94 (0.76-1.16), I^2=0%) and also in the sensitivity analysis (pooled OR 1.23 (0.52-2.89), I^2=0%). The latter was based on two studies, both from China (**Supplementary Figure 7**).(16,53)

4. Discussion:

Hypertension, diabetes mellitus, cerebrovascular disease, and ischemic heart disease are co-morbidities which are commonly prevalent and found to be responsible for adverse prognosis in patients with COVID-19.(54) RAAS blockers are used in majority of these diseases and are known for their disease modifying roles in ischemic heart disease, congestive heart failure, and diabetic nephropathy. With the observation that SARS-CoV-2 binds preferentially to ACE2 as its receptor and that ACE2 is prone to upregulation by RAAS blockers, speculations were made that the continuation of RAAS blockers would increase binding of the virus to host cells and enhance its infectivity. On the contrary, ACE2 is known to be protective against lung injury via the Ang (1-7)-Mas-Mrg D axis.(55,56) Ang (1-7) exerts cardiopulmonary protection via vasodilatory, anti -inflammatory, anti-thrombotic and anti-hypertrophic roles.(57) Downregulation of ACE2 has been shown to exaggerate the lung injury and decrease the overall survival of mice subjected to agents with potential pulmonary toxicity.(55,56) Some clinical studies and pooled analyses have shown a protective role of ACEIs against pneumonia particularly in elderly patients with hypertension and diabetes mellitus.(58,59) Considering this, some groups have hypothesized that upregulation of ACE2 by RAAS blockers might be protective once the virus has entered host cells and therapies causing enhancement of ACE2 might be useful tools in the COVID-19 armamentarium.(60) The confusion surrounding the use of RAAS blockers led

to a spurt of observational studies with a focus on establishing relationship if any, between the use of RAAS blockers and COVID-19 outcomes. In this systematic review, we have tried to compile information from all such studies and provide insights on association between the use of RAAS blockers and COVID-19 morbidity and mortality outcomes.

In our meta-analysis, use of RAAS blockers was not associated with an increased risk of mortality. A reduced risk of mortality was seen in the Chinese population, but the effect was nullified in sensitivity analysis. RAAS blockers were found to reduce mortality in hypertensive patients. On the other hand, an increased risk of composite outcome of ICU admission/death was seen with the use of RAAS blockers and this effect persisted in sensitivity analysis.

With respect to severity of COVID-19 disease, although no overall effect of RAAS blockers was evident, a reduced risk of 'critical' form of the disease (defined as per NHC China) was observed. The same protection was not validated, however, in sensitivity analysis. Further, while RAAS blockers did not produce any adverse effect on disease severity when analysed in the entire population, the outcomes differed considerably between the countries. RAAS blockers were found not to affect disease severity in Chinese patients but the use of such agents was associated with nearly a two times higher risk of severe disease in US patients and Europeans. Nearly a four times increased risk of hospitalisation was seen with the use of RAAS blockers in US patients. Similarly, no increase in the risk of ICU admission and invasive ventilation was seen with RAAS blockers in Chinese patients, whereas the US patients on RAAS blockers had an approximately two times higher risk of getting admitted in the ICU or receiving mechanical ventilation. Further, with respect to requirement of corticosteroids and causation of renal injury, no risk could be attributed to RAAS blockers. This interpretation is primarily based on the sensitivity analysis involving Chinese studies.

These country specific variations could be due to the interplay of genetic factors which may include but are not limited to polymorphisms involving *ACE* or *ACE2* genes. *ACE2* gene is prone to multiple polymorphisms. Traditionally, *ACE2* polymorphisms have been associated with hypertension as well as reduced blood pressure lowering response to ACEIs.(61) Some of the polymorphisms seen predominantly in Europeans such as K26R can enhance the interaction between S protein of SARS-CoV-2 and ACE2 which might lead to increased severity of the disease.(62) A preprint analysed the relationship between *ACE2* polymorphisms and severity of COVID-19 disease in a small cohort of 62 patients. Notably, single nucleotide polymorphisms (SNPs) increasing the tissue expression of ACE2 were associated with higher rates of hospitalization while a lower odds of severe disease was seen with SNPs decreasing the tissue expression of ACE2.(63) *ACE* I/D genotype can also influence the severity of COVID-19 pneumonia. Polymorphisms involving *ACE* can influence the circulating and tissue levels of ACE as well as of cytokines like IL-6 and kallikreins. Higher enzyme and cytokine levels are seen in those with ID and DD genotypes.(64) *ACE* DD genotype has been shown to be associated with increased cardiovascular morbidity and increased risk of pneumonia in some studies.(65,66) The pneumonia protective potential of ACEIs is commonly observed in Asians and is linked with *ACE* II and ID genotypes prevalent in the Asian population.(67,68)

A recently published study assessed the relationship between allele frequency ratio of *ACE* I/D genotype and COVID-19 recovery. A trend of lesser severity and early recovery was observed with increasing I/D allele ratio. The study showed that I/D ratio of > 1 is seen in China, Japan and East Asia which are some of the less severely affected countries. On the other hand, I/D ratio of less than 1 (0.4-0.6) has been observed for countries like Italy, the US, Spain, Brazil, and the UK, which are affected the most by the COVID-19 pandemic.(69) The

sole contribution of genotypic variations behind severity and mortality is however unlikely as some countries like India have an I/D ratio of around 0.11 but have considerably low mortality and severity rates of COVID-19 compared to the West. Environmental, biological and immunological factors can also have additive or decisive roles in modulating COVID-19 severity and mortality.(70,71)

The neutral effect of RAAS blockers on mortality and a protective effect in hypertensives, are consistent with the results of some of the already published meta-analyses. However, among these, the study by Pranata specifically included COVID-19 patients with hypertension while those by Grover and Zhang included a major study by Mehra et al which has now been retracted.(72–74) The number of studies included in these systematic reviews varied from 12 to 16; moreover, severity definition varied considerably across the studies and therefore was difficult to interpret. By incorporating a much larger number of studies in our meta-analysis, we could analyse the correlation between RAAS blocker use and severity as per various definitions. Finally, the review tends to associate the use of RAAS blockers with multiple outcomes such as need for hospitalization, ICU admission, invasive ventilation, steroid use and renal insult, which as per our knowledge, have not been addressed in any pooled analyses so far.

This systematic review has some limitations. The pooled analysis is mainly based on observational studies, which are more likely to have study populations with difference in baseline characteristics and co-interventions than randomized controlled trials. The country specific subgroup analysis was based on only a small number of studies. Further, the current meta-analysis aimed to generate data related to RAAS blockers and therefore excluded those studies (n=11) which focussed on ACEI and ARB class in isolation and did not provide information about the outcomes in combined RAAS blocker class. We did not

compare the outcomes between users of ACEIs and ARBs also. However, such analyses can be done in the future to deduce any class specific differences that can potentially influence COVID-19 outcomes.

5. Conclusion

There is a need to investigate racial or region/country specific differences in the clinical outcomes of COVID-19. Genetic polymorphisms may govern the pharmacodynamic response to RAAS blockers in different population groups, as seen in our meta-analysis and should be explored actively in future. There is a need to explore excess risk of ICU admission and mechanical ventilation in the US and increased severity of COVID-19 disease in Europeans, both of which were found to be associated with RAAS blocker usage. Overall, the use of RAAS blockers does not seem to have any impact on COVID-19 mortality and severity. In the presence of a protective effect in patients with hypertension, it may be advisable to continue these drugs in those patients with pre-COVID indication for the same.

Conflicts of Interest: None

Funding Support: None

Acknowledgement: Dr Patel and Dr Kaur wish to thank the administration of the All India Institute of Medical Sciences, Gorakhpur for providing research support.

References:

1. Coronavirus [Internet]. [cited 2020 Aug 28]. Available from: https://www.worldometers.info/coronavirus

2. Xie M, Chen Q. Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis [Internet]. 2020 May;94:119–24. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1201971220302046

3. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;2019.

4. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation [Internet]. 2005 May 24;111(20):2605–10. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.5104 61

5. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertens (Dallas, Tex 1979) [Internet]. 2004 May;43(5):970–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15007027

6. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS One [Internet]. 2016;11(1):e0147601. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26808317

7. Andrea C, Francesco M, Antonio N, Evgeny F, Marzia S, Fabio C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia. Hypertension [Internet]. 2020 Aug;76(2). Available from:

https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15
312

8. Dublin S, Walker RL, Floyd JS, Shortreed SM, Fuller S, Albertson-Junkans LH, et al. Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study. medRxiv [Internet]. 2020 Jan 1;2020.07.06.20120386. Available from: http://medrxiv.org/content/early/2020/07/07/2020.07.06.20120386.abstract

9. Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, et al. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. Am J Hypertens [Internet]. 2020 Jun 8; Available from: https://academic.oup.com/ajh/advance-article/doi/10.1093/ajh/hpaa096/5854703

10. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med [Internet]. 2020 Jun 1;201(11):1380–8. Available from: https://www.atsjournals.org/doi/10.1164/rccm.202002-0445OC

11. Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv [Internet]. 2020 Jan 1;2020.04.08.20057539. Available from: http://medrxiv.org/content/early/2020/04/10/2020.04.08.20057539.abstract

12. Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with COVID-19 Diagnosis and

Mortality. JAMA - J Am Med Assoc. 2020;324(2):168–77.

13. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J [Internet]. 2020 Jun 7;41(22):2058–66. Available from: https://academic.oup.com/eurheartj/article/41/22/2058/5851436

14. Golpe R, Pérez-de-Llano LA, Dacal D, Guerrero-Sande H, Pombo-Vide B, Ventura-Valcárcel P. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Med Clin (Barc) [Internet]. 2020;(xx):6–8. Available from: https://doi.org/10.1016/j.medcli.2020.06.013

15. Hu J, Zhang X, Zhang X, Zhao H, Lian J, Hao S, et al. COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome. J Infect [Internet]. 2020 May 28; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32474032

16. HUANG L, CHEN Z, NI L, CHEN L, ZHOU C, GAO C, et al. Impact of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Inflammatory Responses and Viral Clearance in COVID-19 Patients: A Multicenter Retrospective Cohort Study. 2020;1–24.

17. Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med [Internet]. 2020 Apr;8(7):430–430. Available from: http://atm.amegroups.com/article/view/39307/html

18. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 Patients with COVID-19 in New York: retrospective case series. medRxiv [Internet]. 2020 Jan

1;2020.04.20.20072116. Available from: http://medrxiv.org/content/early/2020/05/07/2020.04.20.20072116.abstract

19. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821–9.

20. Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv [Internet]. 2020 Jan 1;2020.04.24.20077388. Available from: http://medrxiv.org/content/early/2020/04/29/2020.04.24.20077388.abstract

21. Jung S-Y, Choi JC, You S-H, Kim W-Y. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study. Clin Infect Dis [Internet]. 2020 May 22; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa624/5842160

22. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825–30.

23. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol [Internet]. 2020 Jul;146(1):110–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091674920304954

24. Liabeuf S, Moragny J, Bennis Y, Batteux B, Brochot E, Schmit JL, et al.

Association between renin–angiotensin system inhibitors and COVID-19 complications. Eur Hear J - Cardiovasc Pharmacother. 2020;2.

25. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 May 5; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32369097

26. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect [Internet]. 2020 Dec;9(1):757–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32228222

27. Mohamed MMB, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, et al. Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans. Kidney360. 2020;1(7):614–22.

28. López-Otero D, López-Pais J, Cacho-Antonio CE, Antúnez-Muiños PJ, González-Ferreiro T, Pérez-Poza M, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Rev Española Cardiol (English Ed. 2020;(x).

29. Baker KF, Hanrath AT, Loeff IS van der, Tee SA, Capstick R, Marchitelli G, et al. COVID-19 management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases centre a detailed descriptive analysis. Medrxiv [Internet]. 2020;44(0):1–16. Available from: http://medrxiv.org/cgi/content/short/2020.05.14.20100834

30. Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barbé F, et al. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal

Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. Clin Infect Dis [Internet]. 2020 Jul 5; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa677/5867535

31. Regina J, Papadimitriou-Olivgeris M, Burger R, Filippidis P, Tschopp J, Desgranges F, et al. Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. medRxiv [Internet]. 2020 Jan 1;2020.05.11.20097741. Available from: http://medrxiv.org/content/early/2020/05/14/2020.05.11.20097741.abstract

32. Reilev M, Kristensen KB, Pottegaard A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 9519 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark A nationwide cohort. Medrxiv [Internet]. 2020;1–24. Available from: https://doi.org/10.1101/2020.05.24.20111823%0Ahttp://medrxiv.org/cgi/content/short/2020.05.24.20111823

33. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv [Internet]. 2020 Jan 1;2020.04.09.20059964. Available from: http://medrxiv.org/content/early/2020/04/14/2020.04.09.20059964.abstract

34. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med. 2020;382(25):2441–8.

35. Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. medRxiv [Internet]. 2020 Jan 1;2020.05.20.20108555. Available from: http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108555.abstract

36. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA [Internet]. 2020 May 26;323(20):2052. Available from: https://jamanetwork.com/journals/jama/fullarticle/2765184

37. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc. 2020;21(7):909-914.e2.

38. Tan N-D, Qiu Y, Xing X-B, Ghosh S, Chen M-H, Mao R. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. Gastroenterology [Internet]. 2020 May; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508520306624

39. TRECARICHI EM, MAZZITELLI M, SERAPIDE F, PELLE MC, TASSONE B, ARRIGHI E, et al. Characteristics, outcome and predictors of in-hospital mortality in an elderly population from a SARS-CoV-2 outbreak in a long-term care facility. medRxiv [Internet]. 2020;2020.06.30.20143701. Available from: https://www.medrxiv.org/content/10.1101/2020.06.30.20143701v1

40.	Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. Shimosawa T, editor. PLoS One [Internet]. 2020 Jun 24;15(6):e0235248. Available from: https://dx.plos.org/10.1371/journal.pone.0235248

41.	Xie Y, You Q, Wu C, Cao S, Qu G, Yan X, et al. Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19). Circ J. 2020;84(8):1277–83.

42.	Xu J, Huang C, Fan G, Liu Z, Shang L, Zhou F, et al. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020;

43.	Yang G, Yang G, Tan Z, Tan Z, Zhou L, Yang M, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single-center retrospective study. Hypertension. 2020;51–8.

44.	Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. 2020;1–31.

45.	Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res [Internet]. 2020 Jun 5;126(12):1671–81. Available from: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134

46.	Zhou J, Tse G, Lee S, Liu T, Wu WKK, cao zhidong, et al. Identifying

main and interaction effects of risk factors to predict intensive care admission in patients hospitalized with COVID-19: a retrospective cohort study in Hong Kong. medRxiv [Internet]. 2020;2020.06.30.20143651. Available from: http://medrxiv.org/content/early/2020/07/02/2020.06.30.20143651.abstract

47.   Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens [Internet]. 2020 Oct 2;42(7):656–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32404011

48.   Caraballo C, McCullough M, Fuery M, Chouairi F, Keating C, Ravindra N, et al. COVID-19 Infections and Outcomes in a Live Registry of Heart Failure Patients Across an Integrated Health Care System. medRxiv [Internet]. 2020 Jan 1;2020.04.27.20082016. Available from: http://medrxiv.org/content/early/2020/05/03/2020.04.27.20082016.abstract

49.   Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399–407.

50.   Choi HK, Koo H-J, Seok H, Jeon JH, Choi WS, Kim DJ, et al. ARB/ACEI use and severe COVID-19: a nationwide case-control study. medRxiv [Internet]. 2020;2020.06.12.20129916. Available from: http://medrxiv.org/content/early/2020/06/13/2020.06.12.20129916.abstract

51.   de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system

inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–14.

52.   Du B, Si D, Yang B, Liu G, Zhang Q, Yang Y, et al. Modulation of Cardiac Injury by ACE inhibitor/ARB in Patients with Severe COVID-19. 2020;1–11.

53.   Xu J, Huang C, Fan G, Liu Z, Shang L, Zhou F, et al. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med [Internet]. 2020 Jul 3; Available from: http://link.springer.com/10.1007/s11684-020-0800-y

54.   Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis [Internet]. 2020 May;94:91–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1201971220301363

55.   Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol [Internet]. 2008 May;93(5):543–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18448662

56.   Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature [Internet]. 2005 Jul 7;436(7047):112–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16001071

57.   Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC, Llorens-Cortes C, et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev [Internet]. 2019;71(4):539–70. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/31537750

58. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ [Internet]. 2012 Jul 11;345:e4260. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22786934

59. van de Garde EM, Souverein PC, Hak E, Deneer VH, van den Bosch JM, Leufkens HG. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens [Internet]. 2007 Jan;25(1):235–9. Available from: http://journals.lww.com/00004872-200701000-00032

60. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med [Internet]. 2020 Jun;76:14–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32336612

61. Fan X, Wang Y, Sun K, Zhang W, Yang X, Wang S, et al. Polymorphisms of ACE2 Gene are Associated With Essential Hypertension and Antihypertensive Effects of Captopril in Women. Clin Pharmacol Ther [Internet]. 2007 Aug 2;82(2):187–96. Available from: http://doi.wiley.com/10.1038/sj.clpt.6100214

62. Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. bioRxiv [Internet]. 2020 Jan 1;2020.04.23.057042. Available from: http://biorxiv.org/content/early/2020/04/24/2020.04.23.057042.abstract

63. Wooster L, Nicholson CJ, Sigurslid HH, Lino Cardenas CL, Malhotra R. Polymorphisms in the ACE2 Locus Associate with Severity of COVID-19

Infection. medRxiv [Internet]. 2020 Jan 1;2020.06.18.20135152.
Available from:
http://medrxiv.org/content/early/2020/06/22/2020.06.18.20135152.abstrac
t

64. Dai S, Ding M, Liang N, Li Z, Li D, Guan L, et al. Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients. Sci Rep [Internet]. 2019 Dec 23;9(1):19719. Available from: http://www.nature.com/articles/s41598-019-56263-8

65. Morimoto S, Okaishi K, Onishi M, Katsuya T, Yang J, Okuro M, et al. Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Am J Med [Internet]. 2002 Feb;112(2):89–94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002934301010713

66. Brown NJ, Blais C, Gandhi SK, Adam A. ACE Insertion/Deletion Genotype Affects Bradykinin Metabolism. J Cardiovasc Pharmacol [Internet]. 1998 Sep;32(3):373–7. Available from: http://journals.lww.com/00005344-199809000-00006

67. TAKAHASHI T, MORIMOTO S, OKAISHI K, KANDA T, NAKAHASHI T, OKURO M, et al. Reduction of Pneumonia Risk by an Angiotensin I–Converting Enzyme Inhibitor in Elderly Japanese Inpatients According to Insertion/Deletion Polymorphism of the Angiotensin I–Converting Enzyme Gene. Am J Hypertens [Internet]. 2005 Oct;18(10):1353–9. Available from: https://academic.oup.com/ajh/article-lookup/doi/10.1016/j.amjhyper.2005.04.020

68. Sagnella GA, Rothwell MJ, Onipinla AK, Wicks PD, Cook DG, Cappuccio FP. A population study of ethnic variations in the angiotensin-

converting enzyme I/D polymorphism. J Hypertens [Internet]. 1999 May;17(5):657–64. Available from: http://journals.lww.com/00004872-199917050-00009

69. Hatami N, Ahi S, Sadeghinikoo A, Foroughian M, Javdani F, Kalani N, et al. Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: an ecological meta-regression. Endocrine [Internet]. 2020 Jun 15;68(3):479–84. Available from: http://link.springer.com/10.1007/s12020-020-02381-7

70. Chakrabarti SS, Kaur U, Banerjee A, Ganguly U, Banerjee T, Saha S, et al. COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity? Aging Dis [Internet]. 2020;11(3):480. Available from: http://www.aginganddisease.org/EN/10.14336/AD.2020.0402

71. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science (80-) [Internet]. 2020 Aug 4;eabd3871. Available from: https://www.sciencemag.org/lookup/doi/10.1126/science.abd3871

72. Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr [Internet]. 2020 Jun 27;14(5):983–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32615377

73. Zhang X, Yu J, Pan L-Y, Jiang H-Y. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res [Internet]. 2020;158:104927. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32422341

74. Grover A, Oberoi M. A systematic review and meta-analysis to evaluate

the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Hear J - Cardiovasc Pharmacother [Internet]. 2020 Jun 15; Available from: https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa064/5857623

Figure Legends:

Figure 1: Flow diagram of number of studies screened and selected

Figure 2. Overall and region-specific mortality effects of RAAS blockers in COVID-19 patients

Figure 3. Disease/indication specific mortality effects of RAAS blockers in COVID-19 patients

Figure 4. Effects of RAAS blockers on severity of COVID-19 disease (pooled and definition-specific)

Figure 5. Region-specific severity effects of RAAS blockers in COVID-19 patients

Table 1. Studies included in meta-analysis of impact of renin angiotensin aldosterone system blockers on mortality and severity outcomes of COVID-19

Author	Country	Design	Total duration	Follow up per patient	Age (in years)	Sample size studied (M/F)	Indication for RAAS blocker	Outcome tested	Co-morbidities	Confounder adjustment (For included variables)	Quality (NOS score)
Andrea C	Italy	Retrospective	43d	28d	Mean (SD) entire sample 63.4 (14.9)	191 (131/60); HTN=96	HTN	Mortality	In HTN gp-CKD: 41.6%, CAD: 28.1%, DM: 22.9%	No	8
Argenziano MG	USA	Retrospective	61d	NM	Median (IQR) entire sample 63 (50-75)	1000 (596/404)	NM	Severity assessed as hospitalization/ ICU admission/ IV	HTN: 60%, DM: 37%, CAD: 13%	No	7
Baker KF	UK	Retrospective	119d	28d	Median (IQR) 75 (60-83)	316 (173/143)	NM	Mortality	HTN: 42%, Respiratory diseases: 32%, DM: 26.6%	Yes	10
Bean DM	UK	NM	22d	7d	Mean (SD) entire sample 63 (20)	205 (106/99)	NM	Severity ¶	HTN: 51%, DM: 30%, IHD/HF: 14.6%	Yes	10
Bravi F	Italy	Retrospective	NM	24d	Mean (SD) entire sample 58 (20.9)	1603 (758/845); HTN=543	HTN	Severity ¶	HTN: 34%, Major CVD: 16%, DM: 12%	Yes	10
Caraballo C	USA	Retrospective	NM	NM	Median entire sample (IQR) 78 (65-87)	206 (93/113)	HF	Mortality	HTN: 80%, Renal disease: 38.3%, CAD: 35.4%	No	8

Chen Y	China	Retrospective	77d	NM	Median entire sample (IQR) 58 (42-62)	71 (with known history of medication)	DM & HTN	Mortality	HTN: 36.6%, CVD: 14.7%, DM: 14.4%	No	6
Choi HK	South Korea	Retrospective	116d	NM	Mean (SD) Users gp- 65 (13) Non-users group- 68 (15)	1585 (679/906)	HTN	Mortality & Severity ϕ^a	Users gp: DM: 46.5%, Major neurologic diseases: 28% Non-users gp: DM: 43%, Major neurologic diseases: 42.7%	Yes	9
de Abajo F	Spain	Case Control	24d	NM	Mean (SD) entire sample 69.1 (15.4)	1139 (695/444)	NM	Severity ¶	HTN: 54.2%, DLP: 39%, DM: 272%	Yes	10
Du B	China	Retrospective	40d	NM	Median (IQR) Users gp- 71 (63.5-77) Non-users gp- 69 (62-77)	154 (79/75)	Raised Troponin I	Mortality	Users gp- HTN: 100%, DM: 41.2%, CVD: 29.4% Non-users gp- HTN: 38.7%, DM: 19%, CVD: 18.3%	Yes	7
Dublin S	USA	Retrospective	106d	NM	Mean (SD) entire tested sample 66 (12.2)	56105 (29455/ 26650); Tested positive = 720	NM	Severity assessed as hospitalization	Users gp- HTN: 71.5%, DM: 33.5%, Renal disease: 12.2% Non-users gp-	Yes	10

								HTN: 9.9%, DM: 3.8%, Renal disease: 2.3%		
Felice C	Italy	Retrospective	23d	NM	Mean (SD) ACE users 73.1 (11.5) ARB users 69 (13.4) Non-users 76.2 (11.9)	133 (86/47)	HTN	Mortality & Severity assessed as H/ICU/ Non-IV	Users gp-DM: 24%, Cancer: 17%, COPD: 9% Non-users gp-DM: 28%, Cancer: 14%, COPD: 14%	Yes	9
Feng Y	China	Retrospective	46d	NM	Median (IQR) entire sample 53 (40-64)	476 (271/205)	NM	Severity *	DM: 10.3%, CVD: 8%, COPD: 4.6%	No	4
Feng Z	China	Retrospective	59d	NM	Median (IQR) entire sample 47 (36-58)	564 (284/280)	HTN	Severity *	HTN: 14.5%, DM: 8%, CVD: 3.9%	Yes	10
Fosbol EL	Denmark	Retrospective	94d (73d of Nested CC)	NM	Median (IQR) entire sample 54.7 (40.9-72) Users gp-72.8 (61.0-81.0)	4480 (2144/ 2336)	NM	Mortality & Severity[$]	Users gp-HTN: 70.8%, DM: 24.2%, MI: 21.6% Non-users gp- HTN: 5.8%, DM: 5.4%, MI 5.2%	Yes	10

					Non-users gp-50.1 (37.2-64.5)						
Gao C	China	Retrospective	57d	Median (IQR) 21d (12d-32d)	Mean (SD) 64.24 (11.2)	850 (443/407)	HTN	Mortality & Severity*	Users gp-DM: 30.1%, Angina: 17.5%, PCI/CABG: 4.9% Non-users gp-DM: 26.6%, Angina: 15.2$, PCI/CABG: 5.3%	Yes	10
Golpe R	Spain	Retrospective	24d	Mean (SD) 22d (7d)	Mean (SD) 70.4 (12.3)	157 (72/85)	HTN	Severity assessed as hospitalization	DM: 33.7%, DLP: 51.6%	No	9
Guo T	China	Retrospective	32d	NM	Mean (SD) of entire sample 58.5 (14.66)	187 (91/96)	NM	Mortality	HTN: 32.6%, DM: 15%, CHD: 11.2%	No	8
Hu J	China	NM	23d	NM	Median (IQR) 57 (49.5-66)	149 (88/61)	HTN	Mortality & Severity*	Users gp-DM: 24.6%, CLD: 7.7%, Renal disease: 6.1% Non-users gp- DM: 16.7%, CLD: 4.76%, Renal disease: 2.4%	No	5

Author	Country	Study design	Duration		Age	Sample size	Condition	Outcomes	Comorbidities		Score
Huang L	China	Retrospective	40d	NM	Mean (SD) entire sample 58 (17)	200 (115/85)	NM	Mortality & Severity assessed by OF/IV[a]	Users gp- HTN: 75%, DM: 25%, CHD: 18% Non-users HTN: 22%, DM: 14%, CHD: 8%	No	8
Huang Z	China	Retrospective	26d	NM	Mean (SD) Users gp- 52.65 (13.12) Non - users gp- 67.77 (12.84)	50 (27/23)	HTN	Mortality & Severity*	Users gp- COPD, Anaemia: 5%, CAD, DM: 0% Non-users gp- DM: 13.3%, CAD: 3.3%, COPD, anaemia: 0%	No	6
Inciardi RM	Italy	NM	22d	14d minimum	Mean (SD) entire sample 67 (12)	99 (80/19)	NM	Mortality	HTN: 64%, DM: 31%, DLP: 30%	No	6
Ip A	USA	Retrospective	NM	NM	<50 to >80 years	1584 with HTN, 1216 with known outcomes	HTN	Mortality	NM	No	7
Jung SY	South Korea	Cohort study	NM	NM	Mean (SD) Users gp- 62.5 (14.7) Non- users gp-	5179 (2295/2884)	NM	Mortality & Severity assessed as IV	Users gp- HTN: 94%, DM: 48%, COPD: 40% Non-users gp- COPD: 27%, DM: 11%, HTN: 10%,	Yes	10

					41.5 (16.6)						
Li J	China	Retrospective	61d	NM	Median (IQR) entire sample 55.5 (38-67) HTN cohort 66 (59-73)	362 (189/173)	HTN	Mortality & Severity*	Users gp- DM: 36.5%, CbVD, CHD: 23.5% Non-users gp- DM: 34.4%, CHD: 14.2%, CbVD: 16.6%	No	7
Li X	China	Retrospective	38d	32d	Median (IQR) entire sample 60 (48-69)	548 (279/269)	NM	Severity#	HTN: 30.3%, DM: 15.1%, CHD: 6.2%	No	8
Liabeuf S	France	Retrospective	47d	NM	Median (IQR) 73 (61-84)	268 (164 on at least one anti HTN)	NM	Mortality & Severity assessed as ICU admission	HTN: 57%, type 2 DM: 18%, Stroke: 14%	Yes	10
Mehta N	USA	Retrospective	36d	NM	Mean (SD) ACEI gp 63 (15) ARB gp 65 (13)	1735	NM	Mortality & severity assessed as hospitalization/ ICU admission/ IV	ACEI users gp vs non - users gp- HTN: 97% vs 37%, DM: 54% vs 17%, CAD: 21% vs 9% ARB users gp vs non-users gp- HTN: 93% vs 38%, DM: 50% vs 18%, CAD: 24 % vs 9%	Yes	10

Author	Country	Study design	Col4	Col5	Age	Sample (M/F)	Col8	Outcome	Comorbidities	Col11	Score
Meng J	China	Retrospective	44d	NM	Median (IQR) 64.5 (55.8-69)	42 (24/18)	HTN	Mortality & Severity*	Users gp- DM & CHD: 29.4% Non-users gp- DM & CHD: 32%	No	6
Mohamed MMB	Australia	NM	NM	Median 25d, minimum 14d	Non-AKI gp- 66 (23-97) AKI gp- 65 (34-96)	575 (312/263)	NM	Severity assessed as AKI	HTN: 73.7%, DM: 48.8%	No	7
Otero DL	Spain	Retrospective	28d	NM	Mean (SD) 59.5 (20.3) Users gp-72.1 (13.2) Non-users gp- 56 (20.5)	965 (425/540)	NM	Mortality & Severity assessed as hospitalization/HF/ICU admission & composite of HF/death	Users gp- HTN: 98.6%, DLP: 60%, DM: 27.6% Non-users gp- DLP: 19.3%, HTN: 12.1%, DM: 8.7%	Yes	10
Oussalah A	France	Retrospective	31d	NM	Median (IQR) 65 (54-77)	149 (91/58)	NM	Mortality & Severity assessed as acute respiratory failure/ IV	Users gp- HTN: 86%, DM: 58%, CVD: 49% Non-users gp- HTN: 32%, CVD: 19%, DM: 14%	Yes	10
Regina J	Switzerland	Retrospective	25d	14d minimum	Median (IQR) 70 (55-81)	200 (120/80)	NM	Severity assessed as IV	HTN: 43.5%, DM: 21.5%, CAD: 17.5%	No	8
Reilev M	Denmark	NM	64d	30d	Median (IQR) entire sample	9519 (4010/5509)	NM	Mortality & Severity assessed	HTN: 25%, Chronic lung	No	8

					49 (34-63)			as ICU admission/hospitalization	disease: 13%, IHD: 9.1%		
Rentsch CT	USA	Retrospective	52d	NM	Median (IQR) 66.1 (60.4-71)	585 (558/27)	NM	Severity assessed as hospitalization/ ICU admission	HTN: 72.3%, DM: 44.4%, Vascular disease: 27.9%	Yes	10
Reynolds HR	USA	NM	46d	NM	Median (IQR) full sample 49 (34-63) HTN sample 64 (54-75)	5894; HTN=2573	HTN	Severity ¶	HTN: 34.6%, DM: 18%, OLD: 14.6%	Yes	10
Rhee SY	South Korea	NM	NM	NM	Mean (SD) Users gp-64.85 (13.23) Non-users gp-59.9 (16.7)	832 (445/387)	DM	Severity ¶	Users gp-HTN: 99.7%, DLP: 92.6, CVD: 31.2% Non-users gp-HTN: 47.9%, DLP: 84.5%, CVD: 24.7%	Yes	9
Richardson S	USA	NM	35d	NM	Median entire sample (IQR) 63 (52-75)	5700 (3437/226; HTN with known outcomes= 1366	HTN	Mortality & Severity assessed as ICU admission/IV/ AKI	HTN: 56.6%, DM: 33.8&, CAD 11.1%	No	6

De Spiegeleer A	Belgium	Retrospective	47d	NM	Mean (SD) 86 (7)	154 (51/103)	NM	Severity ϕϕ	Users gp- HTN: 93.3%, DM: 20% Non-users gp- HTN: 8.8%, DM: 17.8%	Yes	9
Tan ND	China	Retrospective	71d	30d	Median (IQR) 67 (62-70) in users gp, 67.5 (57-71) in non-users gp	100 (?51/49)	HTN	Mortality & Severity*	Users gp- DM: 25.8%, GI illness: 19.4%, CHD: 16.1% Non-users gp- DM: 29%, GI illness: 24.6%, CHD: 18.8%	No	5
Trecarichi EM	Italy	Retrospective	41d	NM	Mean (SD) 80 (12)	50 (24/26)	NM	Mortality	CVD: 82%, Neurologic disease: 52%, Psychiatric disease: 30%	No	6
Xie Y	China	Retrospective	32d	NM	<65 years- 36.3% ≥65 years- 63.7%	102 (46/56)	ACRI	Mortality & Severity*	HTN: 54%, DM: 22.5%, CHD: 14.7%	No	7
Xu J	China	Retrospective	59d	NM	Median (IQR) 65 (58-73)	101 (53/48)	HTN	Mortality & Severity ¶	Users gp- HTN: 100%, DM: 20%, CHD: 13% Non-users gp- HTN: 100%,	Yes	10

									DM: 18%, CHD: 11%		
Yang G	China	Retrospective	59d	NM	Median (IQR) 66 (61-73), Users gp- 65 (57-72) Non-users gp- 67 (62-75)	126 (62/64)	HTN	Mortality & Severity*	Users gp- DM: 30.2%, Cardiopathy: 16.3%, Neurologic disease: 9.3% Non-users gp- DM: 30%, Cardiopathy: 19.3%, Neurologic disease: 7.2%	No	8
Zeng Z	China	Retrospective	64d	14d minimum	Mean (SD) HTN gp- 67 (11) Users gp- 64 (12) Non-users gp- 69 (10)	75 (41/34)	HTN	Mortality & Severity#	DM: 31%, CVD: 21%, CbVD: 15%	No	6
Zhang P	China	Retrospective	68d	28d	Median (IQR) Users gp- 64 (55-68), Non-users gp- 64 (57-69)	1128 (603/525)	HTN	Mortality (as HR, raw data not available) & Severity assessed as IV & steroid use	Users gp- DM: 23.4%, CHD: 15.4%, CRD: 3.7% Non-users gp- DM: 20.9%, CHD: 10.9%, CRD: 3%	No	7

Zhou J	China	Retrospective	145d	NM	Median (IQR) 35 (32-37)	1043 (563/480), n=976 with known medication history	NM	Severity assessed as ICU admission	Respiratory diseases: 43%, GIT diseases: 32.5%, HTN: 20.2%	No	10
Zhou X	China	Retrospective	27d	NM	Mean (SD) 57.7 (14.2) HTN gp- 64.8 (10.1)	110 (60/50), n=36 with HTN (19/17)	HTN	Mortality	HTN: 32.7%, DM: 10%, CVD: 9.1%	Yes	6

['Users' refers to patients on RAAS blockers, 'non-users' refers to those not on RAAS blockers

¶: Severity in terms of composite of ICU or CCU admission/death; ɸ: Severity in terms of composite of death/ severe infection, latter including respiratory failure or organ failure leading to mechanical ventilation, ICU admission, RRT and ECMO; *: Severity as per Severity Criteria of National Health Commission of China; $: Severity as per SARS/ ICU admission; #: Severity as defined by American Thoracic Society and Infectious Diseases Society of America; !: Valsartan Sacubitril was also taken as ARB; ?: Study did not mention male-female distribution clearly; ɸɸ: DOH ≥ 7d or death; a: The criteria resembled 'Critical' of Chinese criteria and the study data was therefore analysed under the subgroup of 'critical' outcomes as per Chinese definition

Abbreviations: Major CVD: major cardiovascular disease (congestive heart failure, myocardial infarction, or stroke)**;** ACRI: Acute cardiac related injury; AKI: Acute kidney injury; CVD: Cardiovascular disease; CbVD: Cerebrovascular disease; CAD: Coronary artery disease; CHD: Coronary Heart Disease; COPD: Chronic obstructive pulmonary disease; D: Death; DLP: Dyslipidaemia, DM: Diabetes mellitus; d: days; ECMO: Extra corporeal membrane oxygenation; GIT: gastrointestinal tract; gp; group; HF: heart failure; HTN: hypertension; ICU: Intensive Care Unit; IHD: ischemic heart disease; IV: invasive ventilation; NM: not mentioned; NOS: Newcastle-Ottawa scale; OF: organ failure; OLD: Obstructive lung disease; RAAS: Renin angiotensin aldosterone system; RRT: Renal replacement therapy**]**

Table 2. Meta-analysis of all outcomes- summary of results

Parameter	Number of studies (number of patients)	OR (CI)	OR (CI) Sensitivity analysis
Mortality	31 (26432)	0.89 (0.64-1.24), I^2=89%	1.09 (0.71-1.67), I^2=91%
Country/Region specific mortality			
China	15(2465)	0.71 (0.52-0.97), I^2 =0%	0.85 (0.48-1.50), I^2=25%
Europe	10 (16022)	1.19 (0.74-1.91), I^2=89%	1.37 (0.84-2.23), I^2=90%
USA	4 (4406)	0.96 (0.59-1.56), I^2=81%	1.04 (0.39-2.81), I^2=64%
Other Asian (South Korean)	2 (3539)	1.12 (0.18-7.01), I^2=97%	1.12 (0.18-7.01), I^2 =97%
Severity	23 (20127)	1.08 (0.79-1.46), I^2=88%	1.32 (0.93-1.87), I^2=91%
Definition wise severity			
'Critical' (Chinese classification)	8 (3396)	0.50 (0.33-0.76), I^2=29%	0.63 (0.28-1.45), I^2=70%
'Severe' (Chinese classification)	4 (571)	0.71 (0.30-1.69), I^2=54%	0.14 (0.02-1.13)
ICU/death composite	6 (9941)	1.82 (1.31-2.53), I^2=82%	1.82 (1.31-2.53), I^2=82%
Severity (IDSA/ATS)	2 (620)	1.36 (0.49-3.80), I^2=69%	0.86 (0.45-1.61)
Others	3 (5599)	2.14 (1.22-3.74), I^2=69%	2.14 (1.22-3.74), I^2=69%

Country/Region wise severity			
China	13 (3002)	0.69 (0.45-1.06), I^2=51%	0.68 (0.3-1.53), I^2=58%
Europe	7 (8814)	2.08 (1.52-2.85), I^2=77%	2.08 (1.52-2.85), I^2=77%
USA	1 (5894)	1.87 (1.62-2.17)	1.87 (1.62-2.17)
Other Asians	2 (2417)	0.62 (0.32-1.23), I^2=69%	0.62 (0.32-1.23), I^2=69%
Disease wise mortality			
HTN	15 (6060)	0.63 (0.46-0.86), I^2=58%	0.48 (0.36-0.63), I^2=0%
Not specified	12 (19839)	1.58 (1.1-2.27), I^2=82%	1.81 (1.28-2.58), I^2=81%
Others[#]	4 (533)	0.55 (0.31-0.96), I^2=0%	0.62 (0.25-1.50)
Hospitalisation	7 (13849)	2.1 (1.09-4.05), I^2=96%	2.36 (1.2-4.65), I^2=95%
Country/Region wise hospitalisation			
USA	4 (4040)	2.86 (1.13-7.24), I^2=97%	3.87 (1.21-12.34), I^2=97%
Europe	3 (9809)	1.17 (0.20-6.82), I^2=95%	1.17 (0.20-6.82), I^2=95%
ICU admission	13 (16441)	1.37 (0.86-2.19), I^2=91%	1.55 (0.79-3.02), I^2=93%
Country/Region wise ICU admission			
USA	4 (3376)	1.47 (1.15-1.87), I^2=37%	1.82 (1.29-2.58), I^2=0%
Europe	4 (10154)	1.51 (0.57-4.03), I^2=93%	1.51 (0.57-4.03), I^2=93%
China	3 (350)	0.67 (0.35-1.27), I^2=0%	0.65 (0.25-1.68), I^2=0%
Other Asians	2 (2561)	2.64 (0.08-85.87), I^2=97%	2.64 (0.08-85.87), I^2=97%
Invasive ventilation	15 (10678)	1.06 (0.7-1.59), I^2=80%	1.28 (0.58, 2.83), I^2=88%
Invasive ventilation country wise			
USA	3 (4101)	2.33 (1.02-5.36), I^2=92%	9.72 (4.35-21.71)

Europe	2 (446)	0.64 (0.17-2.46), I^2=86%	0.64 (0.17-2.46), I^2=86%
China	8 (2592)	0.79 (0.55-1.14), I^2=0%	1.03 (0.45-2.37), I^2=50%
Other Asians	2 (3539)	1.24 (0.27-5.66), I^2=92%	1.24 (0.27-5.66), I^2=92%
Corticosteroid use	7 (1854) [All from China]	0.82 (0.65-1.04), I^2=38%	1.01 (0.64-1.6), I^2=35%
AKI	5 (2143)	0.94 (0.76-1.16), I^2=0%	1.23 (0.52-2.89), I^2=0% (Based on 2 Chinese studies)

[#One study each of patients with heart failure, acute cardiac related injury, diabetes mellitus and hypertension, and elevated cardiac biomarkers

Abbreviations: AKI: Acute kidney injury, ATS: American Thoracic Society, CI: Confidence Interval, IDSA: Infectious Disease Society of America, OR: Odds Ratio, ICU: Intensive Care Unit]

References identified through
database searching
1348 (171 PubMed, 1177 from
Google Scholar & preprint
servers)

Duplicates= 104

References after removing duplicates
(n = 1244)

References screened
(n = 1244)

References excluded
(n = 1174)
Irrelevant, not meeting the desired
population, not including RAAS
blockers in therapy, narrative
reviews, animal studies, in vitro
studies

Full-text articles
assessed for eligibility
(n = 70)

Full-text articles excluded, n=22, with
reasons

Raw data not available, n=5
Data not available for combined RAAS
blocker use, n=11
View-points/commentaries/perspectives, n=5
Sample size <10, n=1

Studies included in
qualitative synthesis
(n = 48)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 48)

Study or Subgroup	RAAS blocker users Events	Total	Non users Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
1.2.1 China mortality							
Chen Y 2020	4	32	10	39	2.8%	0.41 [0.12, 1.48]	
Du B 2020	9	17	95	137	3.3%	0.50 [0.18, 1.38]	
Gao C 2020	4	183	19	527	3.2%	0.60 [0.20, 1.78]	
Guo T 2020	7	19	36	168	3.4%	2.14 [0.79, 5.83]	
Hu J 2020	1	65	0	84	0.9%	3.93 [0.16, 98.07]	
Huang L 2020	4	40	17	160	3.1%	0.93 [0.30, 2.95]	
Huang Z 2020	0	20	3	30	1.0%	0.19 [0.01, 3.92]	
Li J 2020	21	115	56	247	4.3%	0.76 [0.44, 1.33]	
Meng J 2020	0	17	1	25	0.9%	0.47 [0.02, 12.14]	
Tan ND 2020	0	31	11	69	1.1%	0.08 [0.00, 1.42]	
Xie Y 2020	2	10	23	92	2.3%	0.75 [0.15, 3.79]	
Xu J 2020	11	40	21	61	3.6%	0.72 [0.30, 1.73]	
Yang G 2020	2	43	11	83	2.4%	0.32 [0.07, 1.51]	
Zeng Z 2020	2	28	5	47	2.1%	0.65 [0.12, 3.58]	
Zhou X 2020	2	15	5	21	2.0%	0.49 [0.08, 2.97]	
Subtotal (95% CI)		**675**		**1790**	**36.2%**	**0.71 [0.52, 0.97]**	
Total events	69		313				

Heterogeneity: Tau² = 0.00; Chi² = 11.47, df = 14 (P = 0.65); I² = 0%
Test for overall effect: Z = 2.18 (P = 0.03)

1.2.2 USA mortality							
Carabello C 2020	7	58	27	148	3.6%	0.62 [0.25, 1.50]	
Ip A 2020	137	460	262	669	4.7%	0.66 [0.51, 0.85]	
Mehta N 2020	8	211	34	1494	3.8%	1.69 [0.77, 3.71]	
Richardson S 2020	130	413	254	953	4.7%	1.26 [0.98, 1.63]	
Subtotal (95% CI)		**1142**		**3264**	**16.8%**	**0.96 [0.59, 1.56]**	
Total events	282		577				

Heterogeneity: Tau² = 0.17; Chi² = 15.86, df = 3 (P = 0.001); I² = 81%
Test for overall effect: Z = 0.17 (P = 0.87)

1.2.3 European mortality							
Andrea C 2020	21	68	13	28	3.6%	0.52 [0.21, 1.27]	
Baker KF 2020	17	78	63	233	4.2%	0.75 [0.41, 1.38]	
Felice C 2020	15	82	18	51	3.8%	0.41 [0.18, 0.92]	
Fosbol EI 2020	181	895	297	3585	4.7%	2.81 [2.29, 3.43]	
Inciardi RM 2020	8	28	11	25	3.1%	0.51 [0.16, 1.59]	
Liabeuf S 2020	17	96	30	172	4.1%	1.02 [0.53, 1.96]	
Otero L 2020	11	210	27	755	3.9%	1.49 [0.73, 3.06]	
Oussalah A 2020	10	43	9	104	3.4%	3.20 [1.20, 8.55]	
Reilev M 2020	187	1428	337	8091	4.8%	3.47 [2.87, 4.19]	
Trecarichi EM 2020	3	16	11	34	2.5%	0.48 [0.11, 2.05]	
Subtotal (95% CI)		**2944**		**13078**	**38.0%**	**1.19 [0.74, 1.91]**	
Total events	470		816				

Heterogeneity: Tau² = 0.44; Chi² = 80.81, df = 9 (P < 0.00001); I² = 89%
Test for overall effect: Z = 0.70 (P = 0.48)

1.2.4 Other Asian Mortality							
Choi HK 2020	48	892	79	693	4.6%	0.44 [0.30, 0.64]	
Jung SY 2020	33	377	51	1577	4.4%	2.87 [1.82, 4.52]	
Subtotal (95% CI)		**1269**		**2270**	**9.0%**	**1.12 [0.18, 7.01]**	
Total events	81		130				

Heterogeneity: Tau² = 1.71; Chi² = 38.99, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 0.12 (P = 0.90)

Total (95% CI)		**6030**		**20402**	**100.0%**	**0.91 [0.65, 1.26]**	
Total events	902		1836				

Heterogeneity: Tau² = 0.60; Chi² = 271.97, df = 30 (P < 0.00001); I² = 89%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi² = 3.51, df = 3 (P = 0.32), I² = 14.6%

0.01   0.1   1   10   100
RAAS blocker users   Non users

Study or Subgroup	RAAS blocker users Events	Total	Non users Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
7.1.1 Indication not mentioned							
Baker KF 2020	17	78	63	233	4.2%	0.75 [0.41, 1.38]	
Fosbol EI 2020	181	895	297	3585	4.7%	2.81 [2.29, 3.43]	
Guo T 2020	7	19	36	168	3.4%	2.14 [0.79, 5.83]	
Huang L 2020	4	40	17	160	3.1%	0.93 [0.30, 2.95]	
Inciardi RM 2020	8	28	11	25	3.1%	0.51 [0.16, 1.59]	
Jung SY 2020	33	377	51	1577	4.4%	2.87 [1.82, 4.52]	
Liabeuf S 2020	17	96	30	172	4.1%	1.02 [0.53, 1.96]	
Mehta N 2020	8	211	34	1494	3.8%	1.69 [0.77, 3.71]	
Otero L 2020	11	210	45	755	4.0%	0.87 [0.44, 1.72]	
Oussalah A 2020	10	43	9	104	3.4%	3.20 [1.20, 8.55]	
Reilev M 2020	187	1428	337	8091	4.7%	3.47 [2.87, 4.19]	
Trecarichi EM 2020	3	16	11	34	2.5%	0.48 [0.11, 2.05]	
Subtotal (95% CI)		**3441**		**16398**	**45.4%**	**1.58 [1.10, 2.27]**	
Total events	486		941				
Heterogeneity: Tau² = 0.26; Chi² = 60.94, df = 11 (P < 0.00001); I² = 82%							
Test for overall effect: Z = 2.49 (P = 0.01)							
7.1.2 HTN							
Andrea C 2020	21	68	13	28	3.6%	0.52 [0.21, 1.27]	
Choi HK 2020	49	892	79	693	4.5%	0.45 [0.31, 0.65]	
Felice C 2020	15	82	18	51	3.8%	0.41 [0.18, 0.92]	
Gao C 2020	4	183	19	527	3.2%	0.60 [0.20, 1.78]	
Hu J 2020	1	65	0	84	0.9%	3.93 [0.16, 98.07]	
Huang Z 2020	0	20	3	30	1.0%	0.19 [0.01, 3.92]	
Ip A 2020	137	460	262	669	4.7%	0.66 [0.51, 0.85]	
Li J 2020	21	115	56	247	4.2%	0.76 [0.44, 1.33]	
Meng J 2020	0	17	1	25	0.9%	0.47 [0.02, 12.14]	
Richardson S 2020	130	413	254	953	4.7%	1.26 [0.98, 1.63]	
Tan ND 2020	0	31	11	69	1.1%	0.08 [0.00, 1.42]	
Xu J 2020	11	40	21	61	3.6%	0.72 [0.30, 1.73]	
Yang G 2020	2	43	11	83	2.4%	0.32 [0.07, 1.51]	
Zeng Z 2020	2	28	5	47	2.1%	0.65 [0.12, 3.58]	
Zhou X 2020	2	15	5	21	2.0%	0.49 [0.08, 2.97]	
Subtotal (95% CI)		**2472**		**3588**	**42.6%**	**0.63 [0.46, 0.86]**	
Total events	395		758				
Heterogeneity: Tau² = 0.14; Chi² = 33.21, df = 14 (P = 0.003); I² = 58%							
Test for overall effect: Z = 2.89 (P = 0.004)							
7.1.3 Other diseases							
Carabello C 2020	7	58	27	148	3.6%	0.62 [0.25, 1.50]	
Chen Y 2020	4	32	10	39	2.8%	0.41 [0.12, 1.48]	
Du B 2020	9	17	95	137	3.3%	0.50 [0.18, 1.38]	
Xie Y 2020	2	10	23	92	2.3%	0.75 [0.15, 3.79]	
Subtotal (95% CI)		**117**		**416**	**12.0%**	**0.55 [0.31, 0.96]**	
Total events	22		155				
Heterogeneity: Tau² = 0.00; Chi² = 0.43, df = 3 (P = 0.93); I² = 0%							
Test for overall effect: Z = 2.12 (P = 0.03)							
Total (95% CI)		**6030**		**20402**	**100.0%**	**0.89 [0.64, 1.24]**	
Total events	903		1854				
Heterogeneity: Tau² = 0.60; Chi² = 273.57, df = 30 (P < 0.00001); I² = 89%							
Test for overall effect: Z = 0.70 (P = 0.48)							
Test for subgroup differences: Chi² = 17.20, df = 2 (P = 0.0002), I² = 88.4%							

0.01 0.1 1 10 100
RAAS blocker users   Non users

Study or Subgroup	RAAS blocker users Events	Total	Non users Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
2.1.1 Severe as per Chinese NHC							
Feng Z 2020	1	16	16	49	1.6%	0.14 [0.02, 1.13]	
Li J 2020	57	115	116	247	5.8%	1.11 [0.71, 1.73]	
Meng J 2020	4	17	12	25	2.8%	0.33 [0.08, 1.31]	
Xie Y 2020	6	10	45	92	2.9%	1.57 [0.41, 5.92]	
Subtotal (95% CI)		158		413	13.2%	**0.71 [0.30, 1.69]**	
Total events	68		189				
Heterogeneity: Tau² = 0.40; Chi² = 6.49, df = 3 (P = 0.09); I² = 54%							
Test for overall effect: Z = 0.77 (P = 0.44)							
2.1.2 Severe as per IDSA							
Li X 2020	19	42	247	503	5.2%	0.86 [0.45, 1.61]	
Zeng Z 2020	15	28	15	47	4.0%	2.46 [0.94, 6.45]	
Subtotal (95% CI)		70		550	9.2%	**1.36 [0.49, 3.80]**	
Total events	34		262				
Heterogeneity: Tau² = 0.38; Chi² = 3.23, df = 1 (P = 0.07); I² = 69%							
Test for overall effect: Z = 0.59 (P = 0.56)							
2.1.3 Severity- Composite of ICU admission or death							
Bean DM 2020	9	46	44	159	4.5%	0.64 [0.28, 1.42]	
Bravi F 2020	104	450	88	1153	6.2%	3.64 [2.67, 4.95]	
de Abajo F 2020	215	497	178	642	6.4%	1.99 [1.55, 2.55]	
Liabeuf S 2020	52	96	64	172	5.6%	1.99 [1.20, 3.31]	
Reynolds HR 2020	336	1374	666	4520	6.6%	1.87 [1.62, 2.17]	
Rhee SF 2020	13	327	21	505	4.9%	0.95 [0.47, 1.93]	
Subtotal (95% CI)		2790		7151	34.2%	**1.82 [1.31, 2.53]**	
Total events	729		1061				
Heterogeneity: Tau² = 0.12; Chi² = 27.15, df = 5 (P < 0.0001); I² = 82%							
Test for overall effect: Z = 3.56 (P = 0.0004)							
2.1.7 Severity-others							
Fosbol El 2020	203	895	373	3585	6.5%	2.53 [2.09, 3.05]	
Otero L 2020	22	210	27	755	5.3%	3.16 [1.76, 5.67]	
Spiegeler AD 2020	6	30	31	124	3.9%	0.75 [0.28, 2.00]	
Subtotal (95% CI)		1135		4464	15.8%	**2.14 [1.22, 3.74]**	
Total events	231		431				
Heterogeneity: Tau² = 0.16; Chi² = 6.38, df = 2 (P = 0.04); I² = 69%							
Test for overall effect: Z = 2.67 (P = 0.008)							
2.1.8 Critical as per Chinese NHC							
Choi HK 2020	77	892	116	693	6.2%	0.47 [0.35, 0.64]	
Feng Y 2020	2	33	68	443	2.7%	0.36 [0.08, 1.52]	
Gao C 2020	2	183	18	527	2.6%	0.31 [0.07, 1.36]	
Hu J 2020	8	65	14	84	4.1%	0.70 [0.28, 1.79]	
Huang L 2020	7	40	18	160	4.0%	1.67 [0.65, 4.33]	
Huang Z 2020	1	20	6	30	1.5%	0.21 [0.02, 1.90]	
Tan ND 2020	3	31	22	69	3.0%	0.23 [0.06, 0.83]	
Yang G 2020	4	43	19	83	3.4%	0.35 [0.11, 1.09]	
Subtotal (95% CI)		1307		2089	27.6%	**0.50 [0.33, 0.76]**	
Total events	104		281				
Heterogeneity: Tau² = 0.09; Chi² = 9.83, df = 7 (P = 0.20); I² = 29%							
Test for overall effect: Z = 3.29 (P = 0.001)							
Total (95% CI)		5460		14667	100.0%	**1.08 [0.79, 1.46]**	
Total events	1166		2224				
Heterogeneity: Tau² = 0.36; Chi² = 178.75, df = 22 (P < 0.00001); I² = 88%							
Test for overall effect: Z = 0.47 (P = 0.64)							
Test for subgroup differences: Chi² = 28.94, df = 4 (P < 0.00001), I² = 86.2%							

0.01   0.1   1   10   100
RAAS blocker users   Non users

Study or Subgroup	RAAS blocker users Events	Total	Non users Events	Total	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
12.1.1 China							
Feng Y 2020	2	33	68	443	2.7%	0.36 [0.08, 1.52]	
Feng Z 2020	1	16	16	49	1.6%	0.14 [0.02, 1.13]	
Gao C 2020	2	183	18	527	2.6%	0.31 [0.07, 1.36]	
Hu J 2020	8	65	14	84	4.1%	0.70 [0.28, 1.79]	
Huang L 2020	7	40	18	160	4.0%	1.67 [0.65, 4.33]	
Huang Z 2020	1	20	6	30	1.5%	0.21 [0.02, 1.90]	
Li J 2020	57	115	116	247	5.8%	1.11 [0.71, 1.73]	
Li X 2020	19	42	247	503	5.2%	0.86 [0.45, 1.61]	
Meng J 2020	4	17	12	25	2.8%	0.33 [0.08, 1.31]	
Tan ND 2020	3	31	22	69	3.0%	0.23 [0.06, 0.83]	
Xie Y 2020	6	10	45	92	2.9%	1.57 [0.41, 5.92]	
Yang G 2020	4	43	19	83	3.4%	0.35 [0.11, 1.09]	
Zeng Z 2020	15	28	15	47	4.0%	2.46 [0.94, 6.45]	
Subtotal (95% CI)		**643**		**2359**	**43.7%**	**0.69 [0.45, 1.06]**	
Total events	129		616				

Heterogeneity: Tau² = 0.27; Chi² = 24.66, df = 12 (P = 0.02); I² = 51%
Test for overall effect: Z = 1.68 (P = 0.09)

12.1.2 Europe							
Bean DM 2020	9	46	44	159	4.5%	0.64 [0.28, 1.42]	
Bravi F 2020	104	450	88	1153	6.2%	3.64 [2.67, 4.95]	
de Abajo F 2020	215	497	178	642	6.4%	1.99 [1.55, 2.55]	
Fosbol EI 2020	203	895	373	3585	6.5%	2.53 [2.09, 3.05]	
Liabeuf S 2020	52	96	64	172	5.6%	1.99 [1.20, 3.31]	
Otero L 2020	22	210	27	755	5.3%	3.16 [1.76, 5.67]	
Spiegeler AD 2020	6	30	31	124	3.9%	0.75 [0.28, 2.00]	
Subtotal (95% CI)		**2224**		**6590**	**38.6%**	**2.08 [1.52, 2.85]**	
Total events	611		805				

Heterogeneity: Tau² = 0.12; Chi² = 26.61, df = 6 (P = 0.0002); I² = 77%
Test for overall effect: Z = 4.56 (P < 0.00001)

12.1.3 Other Asian							
Choi HK 2020	77	892	116	693	6.2%	0.47 [0.35, 0.64]	
Rhee SF 2020	13	327	21	505	4.9%	0.95 [0.47, 1.93]	
Subtotal (95% CI)		**1219**		**1198**	**11.1%**	**0.62 [0.32, 1.23]**	
Total events	90		137				

Heterogeneity: Tau² = 0.17; Chi² = 3.25, df = 1 (P = 0.07); I² = 69%
Test for overall effect: Z = 1.37 (P = 0.17)

12.1.4 USA							
Reynolds HR 2020	336	1374	666	4520	6.6%	1.87 [1.62, 2.17]	
Subtotal (95% CI)		**1374**		**4520**	**6.6%**	**1.87 [1.62, 2.17]**	
Total events	336		666				

Heterogeneity: Not applicable
Test for overall effect: Z = 8.31 (P < 0.00001)

Total (95% CI)		**5460**		**14667**	**100.0%**	**1.08 [0.79, 1.46]**	
Total events	1166		2224				

Heterogeneity: Tau² = 0.36; Chi² = 178.75, df = 22 (P < 0.00001); I² = 88%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi² = 28.65, df = 3 (P < 0.00001), I² = 89.5%

0.01 0.1 1 10 100
RAAS blocker users   Non users